Marcela V. Maus, MD, PhD

Identification and correction of T cell defects in patients with chronic lymphocytic leukemia and impact on T cell therapy.

Patients with chronic lymphocytic leukemia can be treated with a variety of regimens, but only cell therapies such as transplant or genetically-modified T cells (CART19) can be curative. Our research proposes to test the combination of ibrutinib and CART19 in the test tube and in mice to identify how and why combining these two types of therapy could cure CLL.